Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

PURPOSE: To develop a population pharmacokinetic (PK) model for intravitreal ranibizumab in infants with retinopathy of prematurity (ROP) and assess plasma free vascular endothelial growth factor (VEGF) pharmacodynamics (PD). METHODS: The RAnibizumab compared with laser therapy for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fidler, Matthew, Fleck, Brian W., Stahl, Andreas, Marlow, Neil, Chastain, James E., Li, Jun, Lepore, Domenico, Reynolds, James D., Chiang, Michael F., Fielder, Alistair R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422765/
https://www.ncbi.nlm.nih.gov/pubmed/32855889
http://dx.doi.org/10.1167/tvst.9.8.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422765/
https://www.ncbi.nlm.nih.gov/pubmed/32855889
http://dx.doi.org/10.1167/tvst.9.8.43

Ejemplares similares